Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Non-Current Deffered Revenue data on file, last reported at $2.6 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $2.6 million, changed 0.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (changed 0.27% YoY), and the FY2025 annual result was $2.7 million, up 2.85% from the prior year.
• Non-Current Deffered Revenue retreated to $2.6 million in Q1 2026 per NAGE's latest filing, from $2.7 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $4.3 million in Q1 2022 and troughed at $2.6 million in Q1 2026.
• A 5-year average of $3.3 million and a median of $3.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue sank 32.24% in 2024, then grew 3.68% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $4.0 million in 2022, then fell by 16.56% to $3.3 million in 2023, then decreased by 21.21% to $2.6 million in 2024, then climbed by 2.85% to $2.7 million in 2025, then declined by 3.81% to $2.6 million in 2026.
• Business Quant data shows NAGE's Non-Current Deffered Revenue at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.